OTCPK:KWBT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kiwa Bio-Tech Products Group Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s Republic of China. More Details


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has Kiwa Bio-Tech Products Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KWBT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.6%

KWBT

6.6%

US Biotechs

1.8%

US Market


1 Year Return

-98.8%

KWBT

31.5%

US Biotechs

14.2%

US Market

Return vs Industry: KWBT underperformed the US Biotechs industry which returned 31.3% over the past year.

Return vs Market: KWBT underperformed the US Market which returned 14.5% over the past year.


Shareholder returns

KWBTIndustryMarket
7 Day-10.6%6.6%1.8%
30 Day-17.5%-0.9%0.04%
90 Day-26.2%-1.8%9.8%
1 Year-98.8%-98.8%33.7%31.5%16.7%14.2%
3 Year-99.7%-99.7%18.4%12.7%41.6%32.2%
5 Year-96.8%-96.8%16.2%8.2%90.9%69.5%

Price Volatility Vs. Market

How volatile is Kiwa Bio-Tech Products Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kiwa Bio-Tech Products Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KWBT ($0.01) is trading below our estimate of fair value ($0.01)

Significantly Below Fair Value: KWBT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KWBT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KWBT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KWBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KWBT is good value based on its PB Ratio (0.1x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Kiwa Bio-Tech Products Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kiwa Bio-Tech Products Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether Kiwa Bio-Tech Products Group is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kiwa Bio-Tech Products Group's filings and announcementshere.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Kiwa Bio-Tech Products Group performed over the past 5 years?

-13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KWBT is currently unprofitable.

Growing Profit Margin: KWBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KWBT is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.

Accelerating Growth: Unable to compare KWBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KWBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: KWBT has a negative Return on Equity (-68.51%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kiwa Bio-Tech Products Group's financial position?


Financial Position Analysis

Short Term Liabilities: KWBT's short term assets ($22.8M) exceed its short term liabilities ($14.3M).

Long Term Liabilities: KWBT's short term assets ($22.8M) exceed its long term liabilities ($130.2K).


Debt to Equity History and Analysis

Debt Level: KWBT's debt to equity ratio (29.3%) is considered satisfactory.

Reducing Debt: KWBT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: KWBT's debt is not well covered by operating cash flow (6.5%).

Interest Coverage: KWBT is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Kiwa Bio-Tech Products Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KWBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KWBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KWBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KWBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KWBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Wade Li (57 yo)

0.50

Tenure

Mr. Wade Li serves as Chief Executive Officer at Kiwa Bio-Tech Products Group Corporation since March 04, 2020 and serves as its President since 2020. He was one of the founders of Kiwa Bio-Tech Products G ...


Leadership Team

NamePositionTenureCompensationOwnership
Siuhung Wang-Liu
Chairman & Corporate Secretary4.83yrsUS$84.00k0.047%
$ 1.5k
Hon Man Yun
Chief Financial Officer2.42yrsUS$139.03kno data
Xiao Qiang Yu
VP & Director1.17yrsUS$59.93kno data
Wade Li
Acting President & CEO0.50yrno datano data
Yanan Tong
Chief Technology Officer0.67yrno datano data
Qi Wang
VP of Technology & Director13.17yrsno datano data
Weijun Xu
no datano datano data

0.7yrs

Average Tenure

50yo

Average Age

Experienced Management: KWBT's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Siuhung Wang-Liu
Chairman & Corporate Secretary4.83yrsUS$84.00k0.047%
$ 1.5k
Xiao Qiang Yu
VP & Director1.17yrsUS$59.93kno data
Qi Wang
VP of Technology & Director13.17yrsno datano data

4.8yrs

Average Tenure

42yo

Average Age

Experienced Board: KWBT's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 2516.2%.


Top Shareholders

Company Information

Kiwa Bio-Tech Products Group Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kiwa Bio-Tech Products Group Corporation
  • Ticker: KWBT
  • Exchange: OTCPK
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.276m
  • Shares outstanding: 515.97m
  • Website: https://www.kiwabiotech.com

Number of Employees


Location

  • Kiwa Bio-Tech Products Group Corporation
  • International Agriculture Innovation Hub
  • 9th Floor,Yangling Avenue South
  • Yangling
  • Shaanxi Province
  • 712100
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KWBTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2004

Biography

Kiwa Bio-Tech Products Group Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s R ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 06:02
End of Day Share Price2020/09/17 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.